To Artiva’s knowledge, this marks the first patient to receive an allogeneic, off-the-shelf NK cell therapy in a U.S. clinical trial for treatment of an autoimmune disease Data demonstrated AlloNK drove deep depletion of peripheral B-cells and complete responses in relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL) patients in ongoing clinical trial, supporting potential mechanism of…
Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the interview here.
Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). CEO Fred Aslan told the Clinical Trials Arena that the company is currently enrolling patients on the trial with hopes to dose the first patient within H1 2024. Read the full article here.
SAN DIEGO, February 22, 2024 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK® (also known as AB-101) for the treatment of…
Manufacturing time and cost create two of the biggest challenges to making cell therapies available to more patients. Scientists at San Diego-based Artiva Biotherapeutics hope to change that with cancer and autoimmune therapies based on natural killer (NK) cells from donors—allogeneic—that are not genetically modified. Read the article here.
Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis. Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved,…
Artiva recognized for advancing AlloNK®, the first allogeneic, off-the-shelf NK cell therapy with an IND allowance for autoimmune disease AlloNK in combination with rituximab aims to be a safe and effective option for patients with lupus nephritis and has scalable potential for future applications in other autoimmune diseases San Diego, Calif., November 8, 2023 –…
Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by Labiotech.eu to discuss recent milestones including: Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf…
This marks the first IND clearance for an allogeneic, off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease Artiva also announced the formation of an advisory board to provide expertise in advancing innovative cell therapies for lupus and other autoimmune diseases SAN DIEGO, August 16, 2023 — Artiva Biotherapeutics, Inc., a clinical stage company…
Initial activity observed in combination therapy of one billion cells per dose with rituximab; majority of responses were observed in patients who had previously failed autologous CAR-T cell therapy AB-101 was well tolerated at up to four billion cells per dose as a monotherapy; up to 16 doses of AB-101 at one billion cells per…